Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker.

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

At a Senate hearing, Kennedy also said the president has directed him to examine the well-established safety of mifepristone, ...

A short statement from CMS said the agency will consider ways to make Medicare price negotiations, begun under Biden, more ...

Senators challenged Kennedy, who was nominated as health secretary by President Trump, on his long track record of ...